Navigation Links
OrbusNeich's Genous™ Stent Demonstrates Most Rapid Coronary Vessel Healing Compared to Bare Metal and Drug Eluting Stents at 14 Days Post-Implantation
Date:11/9/2011

SAN FRANCISCO, Nov. 9, 2011 /PRNewswire/ -- OrbusNeich today announced that the company's Genous Stent provides the most rapid healing of the coronary vessel compared with bare metal stents and drug eluting stents (DES) at 14 days post-implantation. The data were presented by Ladislav Groch, M.D., of the University Hospital St. Anna, Brno, Czech Republic, in the Featured Clinical Research II session at Transcatheter Cardiovascular Therapeutics (TCT) 2011 in San Francisco.

The prospective, single-center, randomized study compared the endothelial stent coverage of the Blazer™ Cobalt Chromium Stent, the cobalt chromium SolarFlex stent and the biolimus eluting coronary stainless steel Nobori® stent with the Genous Stent, measuring optical coherence tomography (OCT) at 14 days. The percentage of healed struts – a proxy for endothelial coverage, the most powerful predictor of stent thrombosis – was significantly higher in the Genous Stent compared to the analyzed cobalt chromium stents and the DES. Specifically, the Genous Stent had 69.7 percent healed and 5.3 percent malapposed struts compared to 56.7 percent healed and 19.7 percent malapposed struts for the Blazer Stent, 55.2 percent healed and 13.9 percent malapposed struts for the SolarFlex stent and 34 percent healed and 45.7 percent malapposed struts for the Nobori stent.

"These data confirm that the endothelial progenitor cell-capturing Genous Stent accelerates the healing of the coronary vessel wall following percutaneous coronary intervention relative to bare metal stents and DES," said Dr. Groch. "Early healing is a powerful predictor of subacute and late stent thrombosis, and the high percentage of covered struts seen with the Genous Stent potentially minimises the length of dual antiplatelet therapy. This is especially important for patients with an increased risk for bleeding."

The primary endpoint of the study was the percentage of covered struts. Secondary endpoints were the percentage of malapposed struts and the absolute thickness of neointima. The study included 40 patients with stable or unstable angina or non-sustained myocardial infarction (MI) who underwent percutaneous coronary intervention with stent implantation; a total of 44 stents were implanted. The patients were randomized into four groups with 10 patients per group, and a total of 4413 stent struts were analyzed manually.  

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
2. Data Published in Circulation Journal Show OrbusNeichs Genous™ Stent Is Safe and Effective in Elderly Patients
3. Two-Year Follow-Up Data Show Outstanding Clinical Outcomes and Safety for OrbusNeichs Genous™ Stent in Patients at High Risk for Restenosis
4. OrbusNeichs Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
5. Study Confirms that OrbusNeichs Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
6. OrbusNeichs Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011
7. Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeichs Genous™ Stent in Diabetic Patients
8. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
9. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
10. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
11. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017 AccuGenomics, Inc., a diagnostic company based ... that the company has provided an AccuKit to the ... at Chapel Hill and to Qura Therapeutics for evaluation ... quantify HIV reservoir and viral expression in human CD4+ ... Cure Center is a joint initiative between the University ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/10/2017)... Colo. , Aug. 10, 2017  Physical Rehabilitation Network ... located in Lakewood, Colorado . The reputable ... Jeff Lipkin , PT, DPT with his staff of four ... University of Pittsburgh and brings over 10 years of experience ... Belmar PT marks the 10th PRN clinic in ...
Breaking Medicine Technology:
(Date:8/21/2017)... WI (PRWEB) , ... August 21, 2017 , ... ... years, with events taking place all over the country. , Outdoor running increases ... marathon runners are at an increased risk of melanoma, and only half may ...
(Date:8/21/2017)... ... ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse Executive ... of Trustees for a three-year term beginning January 1, 2018. , The ... are committed to the improvement of health in their communities. Founded in 1898, the ...
(Date:8/20/2017)... ... , ... A total solar eclipse will occur across the U.S. on Monday, August ... between the sun and Earth. This rare event will be magnificent to witness, but what ... safe on the road during the total eclipse of the sun. , 1. Plan ahead. ...
(Date:8/19/2017)... ... August 19, 2017 , ... DMG Productions, producers ... Aurum Group in an upcoming episode, slated to air fourth quarter 2017. Check ... the Aurum Group; a company committed to supporting dentistry using the most technologically ...
(Date:8/19/2017)... ... August 19, 2017 , ... The ... the first organization with pending recognition status from the Centers for Disease Control ... group telehealth classes and live video conferencing. , The DPP resulted from ...
Breaking Medicine News(10 mins):